42 completed, 14 recruiting, 14 unknown, 7 not yet recruiting. 33 Phase 1, 22 Phase 2, 17 Not applicable, 9 Phase 3, 7 Phase 4.
Follow Infusions, Intravenous: new trials by email Literature Review of Infusions, Intravenous trials Research Report on Infusions, Intravenous
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Umbilical Cord Mesenchymal Stem Cells Therapy (19#iSCLife®-SA) for Patients With Spinocerebellar Ataxia Intravenous infusion, Intrathecal injection, umbilical cord mesenchymal stem cell - Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2 | Phase 2 | Not yet recruiting | Sclnow Biotechnology Co., Ltd. | 45 | 2026-12-31 | 2026-04-23 |
| Intravenous Lidocaine Plus Port-Site Ropivacaine for Recovery After Laparoscopic Surgery Procedure/Standard care, ropivacaine, Lidocaine (intravenous infusion, perioperative) - Intravenous Lidocaine, Laparoscopic Surgery | Phase 3 | Recruiting | Centre Hospitalier Universitaire, Amiens | 182 | 2026-09-22 | 2026-10-16 |
| A Study to Compare the Bioavailability of Ondansetron Following Nasal (NS003) and IV Administration in Healthy Adults NS003 Ondansetron HCl microspheres powder for nasal application, Ondansetron Solution for IV infusion 8mg - Chemotherapy-Induced Nausea and Vomiting (CINV), Radiotherapy-induced Nausea and Vomiting (RINV) | Phase 1 | Recruiting | Nasus Pharma | 12 | 2026-09-15 | 2026-10-09 |
| Efficacy and Safety of Intravenous Dexamethasone Palmitate Treatments in Acute and Subacute Herpes Zoster Pain intravenous infusion with 4 mg dexamethasone palmitate or 8 mg dexamethasone palmitate - Herpes Zoster Pain | Not applicable | Not yet recruiting | Beijing Tiantan Hospital | 954 | 2026-09-01 | 2026-08-26 |
| Adjuvant Therapy for Potentially Immunotherapy-Responsive Gastric or Gastroesophageal Junction Adenocarcinoma Standard Treatment Group: SOX regimen for up to 6 cycles Oxaliplatin: 130 mg/m², i.v., D1, Q3W; S-1 (Tegafur-Gimeracil-Oteracil Potassium): Oral administration: 40 mg per dose for BSA < 1.25, 50 mg pe, Experimental Immunotherapy Group: Phase I: Combination Therapy Period (First 3 Cycles) Oxaliplatin: 130 mg/m², intravenous infusion, Day 1, every 3 weeks (Q3W), for 3 cycles. Serplulimab: 300 mg, i - Gastric or Gastroesophageal Junction Adenocarcinoma | Phase 2 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 108 | 2026-09-01 | 2026-08-19 |
| Adaptive Dengue Antiviral Platform Trial Molnupiravir 400 mg, VIS513 (a monoclonal antibody), Remdesivir 100mg - Dengue, Antiviral Drugs | Phase 2 | Recruiting | Oxford University Clinical Research Unit, Vietnam | 500 | 2026-04-20 | 2026-09-28 |
| Efficacy and Safety of Anrikefon Injection for the Treatment of Postoperative Pain in Patients Undergoing Totally Laparoscopic Radical Distal Gastrectomy Anruikefen (Intravenous Bolus), Anruikefen (Intravenous Infusion), Placebo Group - Gastrectomy, Postoperative Analgesia | Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 114 | 2026-04-08 | 2026-09-22 |
| Study of Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes in Vitiligo Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes (hUC-MSC-Exos) Intravenous Infusion, Oral Prednisone, Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes (hUC-MSC-Exos) Local Injection - Vitiligo, Mesenchymal Stem Cells | Phase 1 / Phase 2 | Not yet recruiting | Xijing Hospital | 96 | 2026-04-01 | 2026-04-09 |
| Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer Drug: QL1706 5mg/kg, iv drip,d1,Q3W; Albumin-Bound Paclitaxel 125mg/m2, iv drip, d1、d8, Q3W; Lenvatinib 8mg, po, QD - Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer | Phase 2 | Recruiting | Sun Yat-sen University | 40 | 2026-03-23 | 2026-04-15 |
| First-in-Human Study Testing a New Antibody Treatment for Tick-Borne Encephalitis in Healthy Volunteers. Human monoclonal antibody TBE025, intravenous infusion - The Tick-borne Encephalitis Virus (TBEV) | Phase 1 | Not yet recruiting | Giuseppe Pantaleo | 18 | 2026-01-01 | 2026-01-29 |
| Study of QLC5513 in Combination With Epalolimab Tovolimab (QL1706) ± Platinum in Patients With Advanced or Metastatic Malignant Solid Tumors QLC5513 IV infusion, QL1706, IV infusion, platinum, IV infusion - Metastatic Solid Tumors | Phase 1 / Phase 2 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 290 | 2025-12-30 | 2025-12-09 |
| Study on the Therapeutic Effect of Different Infusion Times of Tislelizumab on Postoperative High-risk Hepatocellular Carcinoma Tislelizumab: 200mg, intravenous infusion, Q3W - Hepatocellular Carcinoma | Not applicable | Recruiting | Sir Run Run Shaw Hospital | 33 | 2025-12-01 | 2025-11-24 |
| QL1706 Plus Chemotherapy as Neoadjuvant Therapy for Locally Advanced Cervical Cancer: A Phase II Trial Drug: Drug: QL1706 5mg/kg, iv drip,d1,Q3W;Albumin-Bound Paclitaxel 260mg/m2, iv drip, d1, Q3W;Cisplatin50mg/m2, iv drip, d1, Q3W;Carboplatin AUC 5 ivdrip, d1, Q3W - Neoadjuvant Treatment for Locally Advanced Cervical Cancer | Phase 2 | Recruiting | Affiliated Cancer Hospital & Institute of Guangzhou Medical University | 50 | 2025-10-28 | 2025-12-16 |
| SLV-324 Treatment of Metastatic Solid Tumors SLV-324 intravenous (IV infusion) - Metastatic Solid Tumors | Phase 1 | Recruiting | Solve Therapeutics | 70 | 2025-08-25 | 2026-02-23 |
| Separate and Combined Extrapancreatic Effects of GIP and GLP-1 Intravenous Infusion - Pancreatectomy; Hyperglycemia | Not applicable | Completed | University Hospital, Gentofte, Copenhagen | 12 | 2025-02-19 | 2025-09-09 |
| HAI or IV of Adebrelimab, Combined With Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma HAI Adebrelimab, intravenous infusion (IV) of Adebrelimab (ADE), intravenous infusion (IV) of Bevacizumab (Bev.) - Advanced Hepatocellular Carcinoma (HCC) | Phase 2 | Recruiting | Sun Yat-sen University | 76 | 2025-01-03 | 2026-09-25 |
| A Study of PGN-EDO51 or Placebo in People With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment IV infusion, Placebo - Duchenne Muscular Dystrophy (DMD) | Phase 2 | Withdrawn | PepGen Inc | 2024-12-17 | 2025-06-24 | |
| A Phase I Clinical Trial Evaluating the Safety, Tolerability and Pharmacokinetics of AAPB for Injection Single dose, AAPB by injection, intravenous drip., Single dose, placebo, intravenous drip., Multiple dosing, AAPB for injection, intravenous drip - Acute Ischemic Stroke (AIS) | Phase 1 | Not yet recruiting | Jiangsu Kanion Pharmaceutical Co., Ltd | 56 | 2024-11-14 | 2024-11-08 |
| Safety and Efficacy Trial of a Targeted PSMA Fluorescent Contrast Agent (DGPR1008) for Intraoperative Imaging of Prostate Cancer 0.02mg/kg, 0.04mg/kg - Prostate Cancer Patients Undergoing Radical Prostatectomy | Phase 2 | Completed | Haitao Niu, MD | 24 | 2024-10-30 | 2025-06-17 |
| Comparing Quality of Recovery Between ESPB and IV Lidocaine After Major Breast Cancer Surgery USG ESPB, Intravenous Infusion - Breast Neoplasms | Not applicable | Completed | Chinese University of Hong Kong | 80 | 2024-10-25 | 2025-09-08 |
Showing 20 of 88. Sign in to see all of them.
Leukemia, Myeloid, Acute (4) · Carcinoma, Non-Small-Cell Lung (3) · Anemia (2) · Arthritis, Rheumatoid (2) · Crohn Disease (2) · Ductus Arteriosus, Patent (2) · Heart Failure (2) · Hyperglycemia (2) · Melanoma (2) · Myelodysplastic Syndromes (2) · Acute Kidney Injury (1) · Agnosia (1) · Angina Pectoris (1) · Antisynthetase syndrome (1) · Arthritis (1)
AstraZeneca (3) · GlaxoSmithKline (3) · Mabwell (Shanghai) Bioscience Co., Ltd. (3) · Takeda (3) · BGI, China (2) · Pfizer (2) · Shanghai Junshi Bioscience Co., Ltd. (2) · Sun Yat-sen University (2) · The First Affiliated Hospital with Nanjing Medical University (2) · University Hospital, Gentofte, Copenhagen (2) · Yonsei University (2) · AdventHealth Translational Research Institute (1) · Affiliated Cancer Hospital & Institute of Guangzhou Medical University (1) · Ain Shams Maternity Hospital (1) · Aptose Biosciences Inc. (1)
China (22) · United States (16) · United Kingdom (9) · South Korea (5) · Germany (4) · Australia (3) · Canada (3) · Egypt (3) · Taiwan (3) · Austria (2) · Brazil (2) · Denmark (2) · France (2) · Israel (2) · Japan (2)
Agnieszka Bienert, MSC, PhD (1) · Amr AH Helmy, MD (1) · Andrew A Wolff, MD, FACC (1) · Cathy Hammerman, MD (1) · Daniel Sessler, MD (1) · Dario A Paggiarino, MD (1) · David Bell, MB BCh BAO MRCGP FFPM (1) · Edmund Grzeskowiak, MSC, PhD (1) · Fang Luo (1) · Fernando R Altermatt, MD (1) · Han Liang, MS (1)
PMID 10761648, PMID 11180089, PMID 15676628, PMID 18676355, PMID 19269895, PMID 20685221, PMID 21676290, PMID 22460905, PMID 22925619, PMID 23510802, PMID 23516797, PMID 24339028, PMID 24387819, PMID 24760352, PMID 24792949, PMID 25453536, PMID 25669487, PMID 26080045, PMID 26178412, PMID 26445777, PMID 26885872, PMID 26934941, PMID 27188790, PMID 27407096, PMID 27742444, PMID 27788905, PMID 28434963, PMID 30230263, PMID 30654536, PMID 30733593, PMID 31027480, PMID 32142739, PMID 32335153, PMID 32450917, PMID 32506369, PMID 32599393, PMID 32615072, PMID 32832670, PMID 33122995, PMID 33227231, PMID 33234158, PMID 33278625, PMID 33293006, PMID 33389725, PMID 33649582, PMID 35042554, PMID 35381407, PMID 35492333, PMID 35552677, PMID 37140705
2023 (2), 2014 (1), 2016 (1), 2017 (1)